2026 ESC Guidelines on Cardiac Rehabilitation

Prof. Matthias Wilhelm outlines the updated 2026 ESC Guidelines on Cardiac Rehabilitation at the ESC Congress 2026, focusing on personalized training and modern secondary prevention strategies.

5th Universal Definition of Myocardial Infarction

Prof. Kristin Newby breaks down the new 5th Universal Definition of Myocardial Infarction at the ESC Congress 2026, highlighting refined diagnostic criteria and global clinical consensus.

ENRICH-AF: Edoxaban in Intracranial Hemorrhage Survivors with Atrial Fibrillation

Prof. Ashkan Shoamanesh presents key findings from the ENRICH-AF trial at the ESC Congress 2026. The study evaluates whether edoxaban safely reduces stroke risk in high-risk atrial fibrillation patients with a history of intracranial hemorrhage, highlighting crucial trade-offs between ischemic stroke prevention and major bleeding risks.  

SINGLE-AF: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk

Prof. Boyoung Joung presents findings from the landmark SINGLE-AF trial at the ESC Congress 2026. The study demonstrates that direct oral anticoagulants (DOACs) significantly reduce stroke risk in atrial fibrillation patients at intermediate risk without increasing major bleeding.

From Guidelines to Clinical Impact: GDMT Implementation

Prof. Giuseppe Rosano addresses key challenges in implementing guideline-directed medical therapy at the ESC Congress 2026, exploring strategies to bridge the gap between clinical recommendations and real-world cardiovascular care.

Main Highlights and Key Clinical Takeaways of ESC 2026

Prof. Felix Mahfoud summarizes the main highlights and key clinical takeaways from the ESC Congress 2026, showcasing practice-changing trial results, new guidelines, and breakthroughs across AI, cardiometabolic disease, and interventional cardiology.

Start Early, Start in Hospital: Translating Heart Failure Guidelines into Practice

Prof. Shelley Zieroth addresses the critical importance of early, in-hospital initiation of guideline-directed medical therapy for heart failure at the ESC Congress 2026, highlighting practical strategies to improve patient outcomes during post-discharge transition.

From Guidelines to Clinical Impact: Key Takeaways on GDMT Implementation

Prof. Piotr Ponikowski discusses the critical gap between heart failure guidelines and real-world clinical practice, exploring the missing pieces needed for successful guideline-directed medical therapy (GDMT) implementation.

SWITCH SWEDEHEART: Switching Ticagrelor to Prasugrel in ACS

Prof. Elmir Omerovic presents key results from the SWITCH SWEDEHEART trial at the ESC Congress 2026, evaluating the safety and efficacy of switching from ticagrelor to prasugrel in patients with acute coronary syndromes.

2026 ESC Guidelines for the Management of Heart Failure

Prof. Marianna Adamo outlines the updated 2026 ESC Guidelines for the Management of Heart Failure at the ESC Congress 2026, highlighting essential advances in diagnosis, early therapy initiation, and disease management.

Practical Implementation of the ESC Atrial Fibrillation Guideline

Prof. Michiel Rienstra discusses the practical implementation of the ESC Atrial Fibrillation Guidelines at the ESC Congress 2026, offering actionable strategies to streamline clinical workflows and optimize patient care.

2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease

Prof. Kevin Damman outlines the new 2026 ESC Guidelines for managing cardiorenal syndrome at the ESC Congress 2026, focusing on early intervention, risk stratification, and integrated treatment approaches for co-existing CVD and CKD.

How to Personalise the Treatment of Atrial Fibrillation

Prof. Helmut Puererfellner explores tailored approaches to atrial fibrillation management at the ESC Congress 2026, focusing on patient-specific symptom burdens, ablation vs. medical therapy, and targeted risk factor modification.

Comorbidities Require Special Attention in Atrial Fibrillation

Prof. Ratika Parkash explores the critical role of managing comorbid conditions in atrial fibrillation at the ESC Congress 2026, emphasizing tailored risk factor modification and comprehensive multidisciplinary care.

LDL Cholesterol Management in CAD: From ARMYDA to AMUNDSEN

Prof. Giuseppe Patti tracks the evolution of low-density lipoprotein cholesterol management in coronary artery disease at the ESC Congress 2026, drawing insights from the ARMYDA trials to the landmark AMUNDSEN study to optimize lipid-lowering strategies.

REACT: Prevalence of Silent Atherosclerosis Across Adult Life

Prof. Henning Bundgaard presents landmark data from the REACT study at the ESC Congress 2026, mapping the prevalence of silent atherosclerosis across early to late adulthood and highlighting the role of early vascular imaging in primary prevention.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention